Rosiglitazone and Cardiovascular Risk

被引：0
|
作者：
Kintscher, U. [1 ]
机构：
[1] Charite Univ Med Berlin, Ctr Cardiovasc Res, Inst Pharmakol, Hessische Str 3-4, D-10115 Berlin, Germany
来源：
KARDIOLOGE | 2007年 / 1卷 / 02期
关键词：
D O I：
10.1007/s12181-007-0017-1
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：139 / 141
页数：3
相关论文
共 50 条
  • [21] Rosiglitazone and cardiovascular disease revisited
    Davis, Timothy M. E.
    Prins, Johannes B.
    MEDICAL JOURNAL OF AUSTRALIA, 2010, 193 (03) : 134 - 135
  • [22] THE UTILIZATION OF ROSIGLITAZONE AND PIOGLITAZONE AFTER THE CARDIOVASCULAR RISK-WARNINGS: WAS THERE A DIFFERENTIAL EFFECT?
    Jain, R.
    Mullins, C. D.
    Lee, H.
    Wong, W.
    VALUE IN HEALTH, 2009, 12 (07) : A413 - A413
  • [23] Long-term risk of cardiovascular events with rosiglitazone - A meta-analysis
    Singh, Sonal
    Loke, Yoon K.
    Furberg, Curt D.
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2007, 298 (10): : 1189 - 1195
  • [24] Implications of rosiglitazone and pioglitazone on cardiovascular risk in patients with type 2 diabetes mellitus
    Irons, BK
    Greene, RS
    Mazzolini, TA
    Edwards, KL
    Sleeper, RB
    PHARMACOTHERAPY, 2006, 26 (02): : 168 - 181
  • [25] Reduction of cardiovascular risk-score in metabolic syndrome during an initial therapy with rosiglitazone
    Macic-Dzankovic, Amra
    Dzankovic, Faud
    Pojskic, B.
    Asimi, Z.
    HEALTHMED, 2009, 3 (03): : 314 - 321
  • [26] The effects of rosiglitazone on atherosclerotic progression in patients with Type 2 diabetes at high cardiovascular risk
    Yee, M. S.
    Pavitt, D. V.
    Dhanjil, S.
    Godsland, I. F.
    Richmond, W.
    Johnston, D. G.
    DIABETIC MEDICINE, 2010, 27 (12) : 1392 - 1400
  • [27] ROSIGLITAZONE AND CARDIOVASCULAR RISK: NISSEN AND WOLSKI 2010 UPDATED META-ANALYSIS REVISITED
    Kaul, Sanjay
    Diamond, George A.
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2011, 57 (14) : E552 - E552
  • [28] No causal effects between rosiglitazone and cardiovascular disease or risk factors: a Mendelian randomization study
    LI, X. -M.
    Wu, Z. -J.
    Xu, Z. -l.
    LI, A.
    Liu, M. -Q.
    Song, C. -G.
    Wu, K.
    EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, 2023, 27 (11) : 5280 - 5292
  • [29] Does treatment with rosiglitazone increase cardiovascular risk of patients with type 2 diabetes mellitus?
    Hertzel C Gerstein
    Salim Yusuf
    Nature Clinical Practice Endocrinology & Metabolism, 2007, 3 : 798 - 799
  • [30] Rosiglitazone Revisited An Updated Meta-analysis of Risk for Myocardial Infarction and Cardiovascular Mortality
    Nissen, Steven E.
    Wolski, Kathy
    ARCHIVES OF INTERNAL MEDICINE, 2010, 170 (14) : 1191 - 1201
12345